guest ::
| Home > Publications Database > Expanding our understanding of synucleinopathies: proteinopathy, proteinopenia, and lipidopathy. |
| Home > Publications Database > Expanding our understanding of synucleinopathies: proteinopathy, proteinopenia, and lipidopathy. |
| Journal Article (Review Article) | DZNE-2025-01098 |
;
2025
Wiley-Blackwell
Oxford [u.a.]
This record in other databases: 
Please use a persistent id in citations: doi:10.1111/febs.70011
Abstract: A possible consequence of the process of protein aggregation in neurodegenerative diseases is the depletion of soluble protein species (proteinopenia), which may, at least in some cases, reduce protein function/activity. This concept, which is often overlooked, may play a role in synucleinopathies such as Parkinson's disease (PD), and dementia with Lewy bodies (DLB), where the protein α-synuclein (aSyn) is known to accumulate in insoluble inclusions. aSyn is at the crossroads between cellular proteostasis and lipidostasis networks and, therefore, we must be aware of the complexity we face when we try to understand the molecular basis of synucleinopathies. Importantly, aSyn and β-glucocerebrosidase (GCase), a sphingolipid hydrolase also strongly implicated in PD and DLB, are connected to lipid biology and to protein quality control function. Thus, changes in the normal relationship between these two proteins may shift the balance in the cell and lead to proteinopathy and/or proteinopenia, while also affecting lipidostasis of cells in the brain. Thus, pathological mechanisms that are a consequence of (a) loss-of-function, (b) gain-of-toxic function, and (c) alterations in lipidostasis need to be carefully analyzed and integrated in our study of the molecular underpinnings of neurodegenerative mechanisms. Here, we highlight implications of the depletion of the soluble form of aSyn, and of GCase, and discuss how state-of-the-art 'omics technologies' could be deployed to assist in the clinical assessment of synucleinopathies.
Keyword(s): Humans (MeSH) ; alpha-Synuclein: metabolism (MeSH) ; alpha-Synuclein: genetics (MeSH) ; Synucleinopathies: metabolism (MeSH) ; Synucleinopathies: pathology (MeSH) ; Synucleinopathies: genetics (MeSH) ; Parkinson Disease: metabolism (MeSH) ; Parkinson Disease: pathology (MeSH) ; Parkinson Disease: genetics (MeSH) ; Glucosylceramidase: genetics (MeSH) ; Glucosylceramidase: metabolism (MeSH) ; Lipid Metabolism (MeSH) ; Animals (MeSH) ; Proteostasis: genetics (MeSH) ; Lewy Body Disease: metabolism (MeSH) ; Lewy Body Disease: pathology (MeSH) ; Lewy Body Disease: genetics (MeSH) ; Parkinson's disease ; alpha‐synuclein ; lipids ; protein aggregation ; synucleinopathy ; transcription ; alpha-Synuclein ; Glucosylceramidase
; 
; 
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
PDF
PDF (PDFA)